Sigyn Therapeutics (SIGY) Enterprise Value (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Enterprise Value of -$85571.0 for Q3 2025, down 18542.92% sequentially from -$459.0 in Q2 2025, and up 48.07% YoY from -$57790.1 in Q3 2024.
Sigyn Therapeutics (SIGY) Enterprise Value (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Enterprise Value for 10 years, with the latest figure at -$85571.0 in Q3 2025.
- Quarterly Enterprise Value rose 48.07% year-over-year to -$85571.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$85571.0 (up 48.07% YoY) and the FY2024 annual result came in at -$12144.0, down 3.88% from the prior year.
- Enterprise Value eased to -$85571.0 in Q3 2025 per SIGY's latest filing, from -$459.0 in the prior quarter.
- Over five years, Enterprise Value peaked at -$459.0 in Q2 2025 and troughed at -$1.1 million in Q2 2021.
- A 5-year average of -$148461.3 and a median of -$32838.0 in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2022: Enterprise Value sank 116383.19% in 2021, then surged 99.31% in 2022.
- Over 5 years, Enterprise Value stood at -$340956.0 in 2021, then jumped by 97.55% to -$8356.0 in 2022, then tumbled by 39.9% to -$11690.0 in 2023, then declined by 3.88% to -$12144.0 in 2024, then tumbled by 604.64% to -$85571.0 in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$85571.0, -$459.0, and -$12895.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -85,571.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -85,571.00 |
| Jun 30, 2025 | -459.00 |
| Mar 31, 2025 | -12,895.00 |
| Dec 31, 2024 | -12,144.00 |
| Sep 30, 2024 | -164,788.00 |
| Jun 30, 2024 | -53,644.00 |
| Mar 31, 2024 | -32,838.00 |
| Dec 31, 2023 | -11,690.00 |
| Sep 30, 2023 | -64,584.00 |
| Jun 30, 2023 | -23,633.00 |
| Mar 31, 2023 | -322,327.00 |
| Dec 31, 2022 | -8,356.00 |
| Sep 30, 2022 | -28,123.00 |
| Jun 30, 2022 | -7,291.00 |
| Mar 31, 2022 | -81,385.00 |
| Dec 31, 2021 | -340,956.00 |
| Sep 30, 2021 | -502,976.00 |
| Jun 30, 2021 | -1.06 Mn |
| Mar 31, 2021 | -7,107.00 |
| Dec 31, 2020 | -84,402.00 |